Cancer Resources

Addressing Serious Unmet Medical Needs through Targeted Cancer Therapy

Advancing treatment options for advanced solid tumors and hematological malignancies (also known as blood cancers) is a key focus of our work with engineered human enzymes. We believe this work can lead to targeted cancer therapies with the power to improve clinical outcomes and patients’ lives.

But it can’t happen without individuals, families, physicians, and scientists coming together as a community to help those with a diagnosis of cancer.

To this end we’ve compiled information about our product candidates’ clinical trials and related resources.

Current Clinical Trials

To develop an investigational therapy into a fully approved therapeutic option a rigorous “phased” approach is required. In each phase, specific goals must be accomplished before the next phase can begin.

Included in our portfolio of engineered human enzymes with high therapeutic potential are treatment candidates in different phases of development for a variety of cancer indications. Details below:

A Phase 1 Dose-Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Refractory to Hypomethylating Agents

  • Drug: AEB1102(Pegzilarginase) – Co-ArgI-PEG modified human Arginase I
  • Phase: Phase 1
  • Study Type: Interventional
  • Endpoint Classification: Safety/Efficacy Study
  • Intervention Model: Single Group Assignment
  • Masking: Open Label
  • Primary Purpose: Treatment
  • Indication: Acute Myeloid Leukemia, Myelodysplastic Syndrome
  • Status: Active
  • Additional Information: https://clinicaltrials.gov/ct2/show/study/NCT02732184?term=aeglea&rank=1

A Phase I Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients With Advanced Solid Tumors

  • Drug: AEB1102(Pegzilarginase) – Co-ArgI-PEG modified human Arginase I
  • Phase: Phase 1
  • Study Type: Interventional
  • Endpoint Classification: Safety/Efficacy Study
  • Intervention Model: Single Group Assignment
  • Masking: Open Label
  • Primary Purpose: Treatment
  • Indication: Advanced Cancers
  • Status: Active
  • Additional Information: https://clinicaltrials.gov/ct2/show/NCT02561234?term=aeglea&rank=2

Thank you to the patients, families and physicians who contribute to our collective knowledge and to the potential of future therapies by considering involvement in clinical trials.

At present, Aeglea Biotherapeutics is not providing experimental therapeutic agents outside of the clinical trial setting. As part of our dedication to changing patients’ lives, we are currently developing a new policy that will address Aeglea’s process to determining patient access to investigational therapeutic agents for compassionate use.